Literature DB >> 22583460

Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm.

Carlos K H Wong1, Cindy L K Lam, Donna Rowen, Sarah M McGhee, Ka-Ping Ma, Wai-Lun Law, Jensen T C Poon, Pierre Chan, Dora L W Kwong, Janice Tsang.   

Abstract

OBJECTIVES: To map Functional Assessment of Cancer Therapy-General (FACT-G) and Functional Assessment of Cancer Therapy-Colorectal (FACT-C) subscale scores onto six-dimensional health state short form (derived from short form 36 health survey) (SF-6D) preference-based values in patients with colorectal neoplasm, with and without adjustment for clinical and demographic characteristics. These results can then be applied to studies that have used FACT-G or FACT-C to predict SF-6D utility values to inform economic evaluation.
METHODS: Ordinary least square regressions were estimated mapping FACT-G and FACT-C onto SF-6D by using cross-sectional data of 537 Chinese subjects with different stages of colorectal neoplasm. Mapping functions for SF-6D preference-based values were developed separately for FACT-G and FACT-C in four sequential models for addition of variables: 1) main-effect terms, 2) squared terms, 3) interaction terms, and 4) clinical and demographic variables. Predictive performance in each model was assessed by the R(2), adjusted R(2), predicted R(2), information criteria (Akaike information criteria and Bayesian information criteria), the root mean square error, the mean absolute error, and the proportions of absolute error within the threshold of 0.05 and 0.10.
RESULTS: Models including FACT variables and clinical and demographic variables had the best predictive performance measured by using R(2) (FACT-G: 59.98%; FACT-C: 60.43%), root mean square error (FACT-G: 0.086; FACT-C: 0.084), and mean absolute error (FACT-G: 0.065; FACT-C: 0.065). The FACT-C-based mapping function had better predictive ability than did the FACT-G-based mapping function.
CONCLUSIONS: Models mapping FACT-G and FACT-C onto SF-6D reached an acceptable degree of precision. Mapping from the condition-specific measure (FACT-C) had better performance than did mapping from the general cancer measure (FACT-G). These mapping functions can be applied to FACT-G or FACT-C data sets to estimate SF-6D utility values for economic evaluation of medical interventions for patients with colorectal neoplasm. Further research assessing model performance in independent data sets and non-Chinese populations are encouraged.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22583460     DOI: 10.1016/j.jval.2011.12.009

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  14 in total

1.  The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.

Authors:  Nick Kontodimopoulos
Journal:  Qual Life Res       Date:  2014-11-13       Impact factor: 4.147

2.  Improving the mapping of condition-specific health-related quality of life onto SF-6D score.

Authors:  Yingsi Yang; M Y Wong; Cindy L K Lam; Carlos K H Wong
Journal:  Qual Life Res       Date:  2014-03-29       Impact factor: 4.147

3.  Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.

Authors:  Azin Nahvijou; Hossein Safari; Mahmood Yousefi; Marziyeh Rajabi; Morteza Arab-Zozani; Hosein Ameri
Journal:  Breast Cancer       Date:  2020-07-25       Impact factor: 4.239

4.  Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15.

Authors:  Christine Mpundu-Kaambwa; Gang Chen; Remo Russo; Katherine Stevens; Karin Dam Petersen; Julie Ratcliffe
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

5.  Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.

Authors:  Hosein Ameri; Mahmood Yousefi; Mehdi Yaseri; Azin Nahvijou; Mohammad Arab; Ali Akbari Sari
Journal:  J Gastrointest Cancer       Date:  2020-03

6.  Measurement invariance of the Functional Assessment of Cancer Therapy-Colorectal quality-of-life instrument among modes of administration.

Authors:  Carlos K H Wong; Cindy L K Lam; Brendan Mulhern; Wai-Lun Law; Jensen T C Poon; Dora L W Kwong; Janice Tsang
Journal:  Qual Life Res       Date:  2012-09-28       Impact factor: 4.147

7.  Clinical correlates of health preference and generic health-related quality of life in patients with colorectal neoplasms.

Authors:  Carlos K H Wong; Cindy L K Lam; Jensen T C Poon; Dora L W Kwong
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

8.  Health-related quality of life and risk of colorectal cancer recurrence and All-cause death among advanced stages of colorectal cancer 1-year after diagnosis.

Authors:  Carlos K H Wong; Wai-Lun Law; Yuk-Fai Wan; Jensen Tung-Chung Poon; Cindy Lo-Kuen Lam
Journal:  BMC Cancer       Date:  2014-05-17       Impact factor: 4.430

9.  Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.

Authors:  Paulos Teckle; Helen McTaggart-Cowan; Kim Van der Hoek; Stephen Chia; Barb Melosky; Karen Gelmon; Stuart Peacock
Journal:  Health Qual Life Outcomes       Date:  2013-12-01       Impact factor: 3.186

10.  From KIDSCREEN-10 to CHU9D: creating a unique mapping algorithm for application in economic evaluation.

Authors:  Gang Chen; Katherine Stevens; Donna Rowen; Julie Ratcliffe
Journal:  Health Qual Life Outcomes       Date:  2014-08-29       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.